The Conversation (0)
More Featured Articles and Inverviews
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Latest News
Outlook Reports world
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.